DREAMM-20: This study aims to determine the recommended dose level, safety and effectiveness of a drug called belantamab when given alone and in combination with other treatments in people with multiple myelomaA Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

Inclusion

• Participants at the time of signing the Informed Consent Form (ICF) are at least 18 years old or are of the legal age of consent in the jurisdiction in which the study is taking place.
• Participants who have histologically or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the IMWG, and measurable disease.
• PART 1: Participants who have received at least 3 prior lines of anti-myeloma treatments, and have already received an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 mAb (unless contraindicated or unavailable). Lines of therapy are defined by consensus panel of the International Myeloma Workshop.
• PART 2: Participants who meet all of the following:
• Have undergone Autologous stem cell transplant (ASCT) or are considered transplant ineligible
• Have been previously treated with at least ONE prior line of MM therapy
• Have documented disease progression during or after their most recent therapy
• PART 3: Participants who meet both of the following:
• NDMM with a requirement for treatment as documented per IMWG criteria

• Not considered a candidate for high dose chemotherapy with ASCT due to:

  1. Age ≥ 65 years OR
  2. Age 18-65 years with presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT or who refuse high-dose chemotherapy with ASCT as an initial treatment.
• Participants capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and protocol.